Nektar Therapeutics
NASDAQ:NKTR
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
US |
Nektar Therapeutics
NASDAQ:NKTR
|
333.3m USD | -0.2 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -15 979 072.3 | |
US |
Eli Lilly and Co
NYSE:LLY
|
737.5B USD | -197.6 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 81.4 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 13 236.9 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
368.4B USD | 19.9 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.1B USD | 32.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
187.6B GBP | 415.8 | ||
CH |
Roche Holding AG
SIX:ROG
|
188.4B CHF | 38.8 | ||
CH |
Novartis AG
SIX:NOVN
|
181.2B CHF | 20.4 | ||
US |
Pfizer Inc
NYSE:PFE
|
162.7B USD | 45.8 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.